跳至主要内容
临床试验/NCT03850106
NCT03850106已完成不适用

Effects of INDUS810 on Body Composition, Muscular Performance, and Training Adaptations During 12-weeks of Supplementation and Concurrent Training

The Center for Applied Health Sciences, LLC1 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2018年7月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
67
试验地点
1
主要终点
Body composition

研究概览

简要总结

The purpose of this 12-week, interventional study is to determine the effects of oral supplementation with Indus810 (dietary supplement with active ingredient Fenugreek) on body composition, muscular performance, and training adaptations

详细描述

This 12-week study is a randomized, parallel-group, placebo-controlled, clinical trial of N=66 recreationally, but normal to moderately overweight/obese male subjects to be recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences).

Subjects will attend 4 study visits. At Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work, background baseline diet). At Visits 2 (day 0 - Baseline Testing), and 4 (week 12), measurements of various hemodynamic, hematologic & biochemical biomarkers of safety (Total testosterone, CBC, and comprehensive metabolic panel) will be made. At Visits 2, 3, and 4, the following efficacy measures will be obtained: Body Composition assessment via DEXA, Upper and Lower Body Performance testing on a Smith Machine and a TENDO unit utilizing the bench press and squat exercises, and anchored 100mm VAS scales (for various psychometric indices). In addition, a comprehensive side effect profile/ adverse event monitoring will take place throughout the 12-week study duration.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Provide voluntary signed and dated informed consent.
  • •Be in good health as determined by medical history and routine blood chemistries.
  • •Age between the ages of 18 and
  • •Body Mass Index (BMI):
  • •22-25; Waist:Hip Ratio 0.9-1
  • •25-35; Waist:Hip Ratio 0.85-1
  • •Normotensive (supine, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
  • •Normal supine, resting heart rate (<90 per minute).
  • •Willing to duplicate their previous 24-hour diet, and fast for 8-10 hours prior each of the treatments.
  • •Has been participating in regular exercise training, at least 3 days per week, for the past 1-2 months.

排除标准

  • •History of diabetes.
  • •Use of any pre-workout or creatine containing products in the last 4 weeks.
  • •History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • •Prior gastrointestinal bypass surgery (Lapband, etc.).
  • •Other known gastrointestinal or metabolic diseases that might impact absorption or amino acid metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
  • •Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). -Known sensitivity to any ingredient in the test formulations as listed in the Certificates- of-Analysis.
  • •Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
  • •Concomitant use of corticosteroids or testosterone replacement therapy (ingestion, injection, or transdermal).
  • •Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo (microcrystalline cellulose)

干预措施: Placebo (Dietary Supplement)

Indus810

Active Comparator

Indus810 ( 500mg/d)

干预措施: Indus810 (Dietary Supplement)

结局指标

主要结局

Body composition

时间窗: Change in score from Day 0 to day 56 and from day 0 to day 84

body fat percentage (%)

次要结局

  • Upper body strength(Change in pounds from Day 0 to day 56 and from day 0 to day 84)

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Jennifer Sandrock

Chief Operating Officer

The Center for Applied Health Sciences, LLC

研究点 (1)

Loading locations...

相似试验